Eli Lilly, Merck Lead Market Cap Stock Movers on Wednesday…
In the closing of the recent trading day, Merck (MRK) stood at $78.56, denoting a +1.24% move from the preceding…
Nachdem der deutsche Leitindex am Donnerstag erneut den Rückwärtsgang eingelegt und die 21-Tage-Linie nicht überwunden hat, dürfte der Start in…
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRKs momentum and BMY navigating generic headwinds.…
…
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
FRANKFURT (dpa-AFX) - Die Bestellung des neuen Konzernchefs Kai Beckmannhat bei Merck KGaA am Donnerstag zumindest für etwas Erleichterung…
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA auf "Overweight" mit einem Kursziel von…
Frankfurt (www.aktiencheck.de) - Merck-Aktienanalyse von XTB:Die Merck-Aktie (ISIN: DE0006599905, WKN: 659990, Ticker-Symbol: MRK, NASDAQ OTC-Symbol: MKGAF) zeigt seit mehreren Jahren…
The latest trading day saw Merck (MRK) settling at $80.4, representing a -1.36% change from its previous close.…
FDA clears MRKs Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.…
…
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.…
The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a…
(neu: Aussagen aus der Pressekonferenz, Details, Analyst, Aktienkurs) DARMSTADT (dpa-AFX) - Die Dollar-Schwäche hat dem Merck-Konzern …
DARMSTADT (dpa-AFX) - Die Dollar-Schwäche hat dem Merck-Konzern ein unerwartet schwaches zweites Quartal eingebrockt. Zwar konnten die Darmstädter organisch…
Der deutsche Pharmakonzern verpasst beim operativen Ergebnis die Erwartungen. Und auch der Ausblick fällt trüb aus. Dabei wachsen die zwei…
DARMSTADT (dpa-AFX) - Die Dollar-Schwäche hat beim Darmstädter Merck-Konzern für ein unerwartet schwaches zweites Quartal gesorgt. Der Umsatz ging um…
Image source: The Motley Fool.
DATEMonday, July 28, 2025 at 9:00 p.m. ETCALL PARTICIPANTSPresident & CEO — Michael M. MorrisseyChief Financial…
Key PointsRevenue (GAAP) missed expectations, falling to $156.8 million in Q2 2025—down approximately 14% from the prior year quarter and…
Global New Material International Holdings Limited: Frankfurt (ots/PRNewswire) - Global New Material International Holdings Limited („GNMI" oder „die Gruppe") (6616.HK),…
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.…
…
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of…
Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the…
Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring…
Wien (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt…
RAHWAY (dpa-AFX) - Der Pharmakonzern Merck & Co plant nach einem Umsatz- und Gewinnrückgang im…
Key Points- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by…
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer…
Merck to cut jobs and costs as demand for Gardasil in China remains weak…
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares moved lower in early trade as the pharmaceutical company reported second quarter earnings…
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.…
Key PointsCompanies must pass key tests to be included in the Schwab U.S. Dividend Equity ETF.This fund has averaged a…
Key growth drivers include rising demands for high-sensitivity diagnostics and personalized medicine, advancements in genomics, proteomics, and AI-driven innovations, and…
Key PointsSummit Therapeutics leading candidate is showing promise in a key oncology market.The medicine could earn plenty of indications across…
Key PointsCRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential remaining.Viking Therapeutics is targeting…
Key PointsMerck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another acquisition that…
Key PointsPfizer stands as one of the largest pharmaceutical companies in the world.Although it has an attractive 7.1% yield, it…
Key PointsThe Schwab U.S. Dividend Equity ETF is a passive income machine.This ETF is also attractively valued and has delivered…
In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding…
DJ NACHBÖRSE/XDAX -0,4% auf 24.191 Pkt - Merck mit bedingter EU-Zulassung für Ezmekly DOW JONES--Die Merck KGaA hat eine bedingte…
DOW JONES--Die Merck KGaA hat eine bedingte Zulassung für die Vermarktung des Medikaments Ezmekly in der EU erhalten. Wie der…
…
LLYs explosive growth from Mounjaro and Zepbound outpaces MRKs Keytruda-led gains, despite valuation concerns.…
…
Key PointsMerck aims to boost its business by buying Verona Pharma for $10 billion.Through the deal, it will add Ohtuvayre…
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street…
In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding…
Key PointsPros for the Schwab U.S. Dividend Equity ETF include a high yield, impressive dividend growth, and low costs.Cons include…